Argenx names new CEO; Van Hauwermeiren to become chair

After nearly 18 years at Argenx SE (Euronext:ARGX; NASDAQ:ARGX), co-founder Tim Van Hauwermeiren is moving from CEO to chairman of the biotech. Stepping up to CEO will be current COO Karen Massey, who joined the Belgian biotech three years ago from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY); she was that company’s SVP of product development and global clinical operations. Van Hauwermeiren led Argenx as it grew from its 2008 launch to its current position as a NASDAQ-listed large-cap biotech with a $52 billion market cap. Its blockbuster immunology product, Vyvgart efgartigimod, had $2.9 billion in sales through the first nine months of 2025. 

Massey’s primary challenge is now not just continuing to grow the Vyvgart franchise, but also to identify the next major pipeline program that could provide Argenx’s next leg of growth. The leadership moves are still subject to shareholder approval at an annual general meeting  scheduled for May 6...